Molecular Targeted Therapy Market Report 2026

The molecular targeted therapy market size has grown strongly in recent years. It will grow from $71.64 billion in 2025 to $77.89 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to cancer genomics research, monoclonal antibody development, oncology drug approvals, hospital oncology centers, clinical trial expansion.

The molecular targeted therapy market size is expected to see strong growth in the next few years. It will grow to $107.64 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to personalized cancer treatment growth, next-generation sequencing adoption, AI-driven drug discovery, global oncology burden, targeted therapy reimbursement. Major trends in the forecast period include expansion of precision oncology, increased adoption of biomarker-based therapies, growth of targeted cancer drug pipelines, integration of companion diagnostics, rising use of combination targeted therapies.

The growing adoption of personalized medicine is anticipated to drive the expansion of the molecular targeted therapy market in the coming years. Personalized medicine is a healthcare strategy that tailors treatment and prevention approaches based on an individual’s genetic makeup, lifestyle, and environmental influences. The rise of personalized medicine is supported by the increasing availability of genetic data, which enables the development of therapies customized to individual genomes, resulting in improved effectiveness and reduced side effects. Personalized medicine facilitates molecular targeted therapy by enabling the analysis of a patient’s tumor to identify specific genetic mutations or biomarkers, allowing clinicians to select therapies that precisely target these abnormalities. This method enhances treatment accuracy while minimizing damage to healthy tissues. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, in 2023, the U.S. Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases, an increase from 6 approvals in 2022. Therefore, the rise of personalized medicine is fueling the growth of the molecular targeted therapy market.

Major companies operating in the molecular targeted therapy market are concentrating on the development of advanced solutions, such as small molecule inhibitors, to improve clinical outcomes across various cancers and chronic conditions. Small molecule inhibitors are low-molecular-weight compounds capable of entering cells easily and blocking specific proteins that contribute to disease progression. For example, in January 2025, Amgen Inc., a US-based pharmaceutical company, launched Lumakras (sotorasib) in combination with Vectibix (panitumumab), which received approval from the U.S. Food and Drug Administration (FDA), a US-based government agency. This therapy is intended for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as confirmed by an FDA-approved diagnostic test. The approval was supported by results from the Phase 3 CodeBreaK 300 trial, which demonstrated that the combination more than doubled progression-free survival compared to the evaluated standard of care, making it the first targeted therapy to achieve this outcome in this chemorefractory patient group.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology pipeline and accelerate the development of innovative cancer treatments by incorporating Seagen’s expertise in antibody-drug conjugate (ADC) technology. Seagen Inc. is a US-based company specializing in the development of monoclonal antibody-based therapies for cancer treatment.

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

North America was the largest region in the molecular targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the molecular targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the molecular targeted therapy market by affecting imports of biologics, small-molecule APIs, gene therapy vectors, and advanced delivery systems. Cancer treatment segments such as lung, breast, and colorectal cancers are most impacted, particularly in North America and Europe due to reliance on international oncology supply chains. Hospitals and research laboratories face increased procurement and development costs. Positively, tariffs are driving local biopharmaceutical manufacturing and oncology research investment.

The molecular targeted therapy market research report is one of a series of new reports that provides molecular targeted therapy market statistics, including molecular targeted therapy industry global market size, regional shares, competitors with a molecular targeted therapy market share, detailed molecular targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the molecular targeted therapy industry. This molecular targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Molecular targeted therapy is an advanced form of cancer treatment that concentrates on inhibiting the growth and spread of cancer cells by disrupting specific molecules involved in tumor progression. Customized according to the genetic and molecular profile of a patient’s tumor, this approach seeks to improve treatment efficacy while reducing damage to healthy cells. By focusing on cancer-specific pathways, it provides a more precise and less toxic option compared to traditional therapies.

The primary types of molecular targeted therapy include monoclonal antibodies, small molecule inhibitors, gene therapy, and cell therapy. Monoclonal antibodies are specially engineered proteins designed to selectively identify and eliminate cancer cells while preserving healthy tissue in molecular targeted therapy. These treatments are delivered through multiple routes of administration, such as oral, injectable, topical, and intravenous. They are applied across various indications, including lung cancer, breast cancer, colorectal cancer, leukemia, and other cancers, and are utilized by end users such as hospitals, clinics, research laboratories, and diagnostic centers.

The molecular targeted therapy market consists of sales of targeted cancer drugs, kinase inhibitors, hormone therapies, and companion diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.